CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes

被引：46

作者：

Constantinides, Vasilios C. ^{[1
]}

Paraskevas, George P. ^{[1
]}

Emmanouilidou, Evangelia ^{[2
]}

Petropoulou, Olga ^{[1
]}

Bougea, Anastasia ^{[1
]}

Vekrellis, Kostas ^{[2
]}

Evdokimidis, Loannis ^{[1
]}

Stamboulis, Eleftherios ^{[1
]}

Kapaki, Elisabeth ^{[1
]}

机构：

[1] Univ Athens, Dept Neurol 1, Eginit Hosp, 72-74 Vassilisis Sofas Ave, Athens 11528, Greece

[2] Acad Athens, Div Basic Neurosci, Biomed Res Fdn, 4 Soranou Ephessiou St, Athens 11527, Greece

来源：

JOURNAL OF THE NEUROLOGICAL SCIENCES | 2017年 / 382卷

关键词：

Cerebrospinal fluid; Biomarkers; Parkinson-plus; a-Synuclein; Tau proteins; Beta amyloid; PROGRESSIVE SUPRANUCLEAR PALSY; MULTIPLE-SYSTEM ATROPHY; CEREBROSPINAL-FLUID BIOMARKERS; CORTICOBASAL DEGENERATION; ALPHA-SYNUCLEIN; CLINICAL-DIAGNOSIS; DISEASE; ACCURACY; CRITERIA;

D O I：

10.1016/j.jns.2017.09.039

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Introduction: Differential diagnosis of Parkinson-plus patients (PSP, CBD, MSA) and Parkinson's disease (PD) patients is often not straightforward, particularly in atypical cases or at the initial stages of the diseases. Classic CSF biomarkers (amyloid-beta - A beta(42), tau protein - tau(T) and phosphorylated tau protein tau(P-181)) are established biomarkers in the diagnosis of Alzheimer's disease (AD). CSF a-synuclein (alpha-syn) has emerged as a promising biomarker in patients with Parkinsonism. The aim of this study was to analyze the CSF biochemical profile of patients with Parkinsonism. Methods: We analyzed the CSF biomarker profile (A beta(42), tau(T), tau(P-181) alpha-syn) and all relevant ratios in 68 patients with Parkinsonism (19 PSP, 15 MSA, 17 CBD, 17 PD) and 18 controls, diagnosed by latest established diagnostic criteria. Results: CBD patients exhibited elevated tau(T) and decreased A beta(42) compared to the other groups. Five CBD, one PSP patient and one control had a typical AD CSF profile. After exclusion of these patients, the tau(T)/A beta(42) ratio was significantly elevated in MSA patients compared to PD patients and provided excellent specificity and adequate sensitivity in their differential diagnosis. Conclusion: CSF biochemical profile analysis is important in distinguishing AD patients with a CBS phenotype from non-AD CBS patients. The tau(T)/A beta(42) ratio is useful in the differential diagnosis of MSA from PD.

引用

页码：91 / 95

页数：5

共 30 条

[1] Cerebrospinal Fluid Tau and Phosphorylated Tau Protein are Elevated in Corticobasal Syndrome [J].

Aerts, M. B. ;

Esselink, R. A. J. ;

Bloem, B. R. ;

Verbeek, M. M. .

MOVEMENT DISORDERS, 2011, 26 (01) :169-173

[2] Criteria for the diagnosis of corticobasal degeneration [J].

Armstrong, Melissa J. ;

Litvan, Irene ;

Lang, Anthony E. ;

Bak, Thomas H. ;

Bhatia, Kailash P. ;

Borroni, Barbara ;

Boxer, Adam L. ;

Dickson, Dennis W. ;

Grossman, Murray ;

Hallett, Mark ;

Josephs, Keith A. ;

Kertesz, Andrew ;

Lee, Suzee E. ;

Miller, Bruce L. ;

Reich, Stephen G. ;

Riley, David E. ;

Tolosa, Eduardo ;

Troester, Alexander I. ;

Vidailhet, Marie ;

Weiner, William J. .

NEUROLOGY, 2013, 80 (05) :496-503

[3] Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis [J].

Augutis, Kristin ;

Axelsson, Markus ;

Portelius, Erik ;

Brinkmalm, Gunnar ;

Andreasson, Ulf ;

Gustavsson, Mikael K. ;

Malmestrom, Clas ;

Lycke, Jan ;

Blennow, Kaj ;

Zetterberg, Henrik ;

Mattsson, Niklas .

MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (05) :543-552

[4] Red blood cells are the major source of alpha-synuclein in blood [J].

Barbour, Robin ;

Kling, Kristin ;

Anderson, John P. ;

Banducci, Kelly ;

Cole, Tracy ;

Diep, Linnea ;

Fox, Michael ;

Goldstein, Jason M. ;

Soriano, Ferdie ;

Seubert, Peter ;

Chilcote, Tarnie J. .

NEURODEGENERATIVE DISEASES, 2008, 5 (02) :55-59

[5] Pathologic heterogeneity in clinically diagnosed corticobasal degeneration [J].

Boeve, BF ;

Maraganore, DM ;

Parisi, JE ;

Ahlskog, JE ;

Graff-Radford, N ;

Caselli, RJ ;

Dickson, DW ;

Kokmen, E ;

Petersen, RC .

NEUROLOGY, 1999, 53 (04) :795-800

[6]

del Campo M, 2012, BIOMARK MED, V6, P419, DOI [10.2217/BMM.12.46, 10.2217/bmm.12.46]

[7] Multiple-system atrophy:: a new α-synuclein disease? [J].

Gai, WP ;

Power, JHT ;

Blumbergs, PC ;

Blessing, WW .

LANCET, 1998, 352 (9127) :547-548

[8] Second consensus statement on the diagnosis of multiple system atrophy [J].

Gilman, S. ;

Wenning, G. K. ;

Low, P. A. ;

Brooks, D. J. ;

Mathias, C. J. ;

Trojanowski, J. Q. ;

Wood, N. W. ;

Colosimo, C. ;

Duerr, A. ;

Fowler, C. J. ;

Kaufmann, H. ;

Klockgether, T. ;

Lees, A. ;

Poewe, W. ;

Quinn, N. ;

Revesz, T. ;

Robertson, D. ;

Sandroni, P. ;

Seppi, K. ;

Vidailhet, M. .

NEUROLOGY, 2008, 71 (09) :670-676

[9] Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders [J].

Hall, Sara ;

Ohrfelt, Annika ;

Constantinescu, Radu ;

Andreasson, Ulf ;

Surova, Yulia ;

Bostrom, Fredrik ;

Nilsson, Christer ;

Widner, Hakan ;

Decraemer, Hilde ;

Nagga, Katarina ;

Minthon, Lennart ;

Londos, Elisabet ;

Vanmechelen, Eugeen ;

Holmberg, Bjorn ;

Zetterberg, Henrik ;

Blennow, Kaj ;

Hansson, Oskar .

ARCHIVES OF NEUROLOGY, 2012, 69 (11) :1445-1452

[10] CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls [J].

Herbert, Megan K. ;

Eeftens, Jorine M. ;

Aerts, Marjolein B. ;

Esselink, Rianne A. J. ;

Bloem, Bastiaan R. ;

Kuiperij, H. Bea ;

Verbeek, Marcel M. .

PARKINSONISM & RELATED DISORDERS, 2014, 20 (01) :112-115

← 1 2 3 →